Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
Latest Information Update: 30 Jan 2023
At a glance
- Drugs CD200AR-L (Primary) ; Glioma lysate vaccine (Primary) ; Imiquimod (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; First in man
- Sponsors OX2 Therapeutics
- 26 Jan 2023 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
- 26 Jan 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2023.
- 13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research